Recent Updates
Recently added Catalysts
ATOS Positive Sentiment Score: 70/100

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

Key Takeaway: Atossa Therapeutics, Inc. has announced that its President and CEO, Dr. Steven Quay, will present at the Jefferies Global Healthcare Conference on June 5, 2025. The event will provide an opportunity for the company to share its innovative approaches in breast cancer treatment, particularly through its lead product candidate, (Z)-endoxifen. A live webcast of the presentation will be available on the Atossa website, and the session will be archived for 30 days for broader access.

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • Atossa is presenting at a major healthcare conference, potentially gaining visibility.
  • The company's commitment to innovative breast cancer treatments highlights its forward-looking approach.
  • The lead product candidate, (Z)-endoxifen, shows promise across various breast cancer settings.

Full Press Release Details

SEATTLE, June 2, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that Dr. Steven Quay, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 7:35 a.m. Eastern Time.
A live webcast of the presentation can be accessed on the Investors section of the Atossa website under "Events and Presentations" at https://investors.atossatherapeutics.com/news-events/events-presentations. The webcast will be archived for 30 days.
About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company's lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including prevention, neoadjuvant, adjuvant, and metastatic settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit atossatherapeutics.com.
SOURCE Atossa Therapeutics Inc

21 %

more press release views with

Frequently Asked Questions

When will Atossa present at the Jefferies Healthcare Conference?

Atossa will present on June 5, 2025, at 7:35 a.m. Eastern Time.

Where can I watch Atossa’s conference presentation?

The presentation can be accessed via a live webcast on Atossa's Investors page.

What is Atossa Therapeutics developing?

Atossa Therapeutics is developing innovative medicines for breast cancer treatment.

What is Atossa's lead product candidate?

(Z)-endoxifen is Atossa's lead product candidate for breast cancer.

What types of breast cancer settings does Atossa address?

Atossa targets prevention, neoadjuvant, adjuvant, and metastatic breast cancer.

Last updated: Jun 2, 2025